Is GRFS a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Grifols (GRFS) rests on Immunoglobulin demand and volume growth: The immunoglobulin franchise is Grifols' growth engine, with Ig sales growing roughly 15 percent in Q1 2026 on strong underlying demand for immune-deficiency and neurology indications. Revenue (FY 2025) is ~EUR 7.5 billion (~$8.2 billion). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Grifols carries a heavy debt load, with leverage still above 4x, so its equity value is sensitive to interest rates, refinancing terms, and any stumble in cash generation. Whether GRFS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Grifols, S.A. is a Spanish healthcare company founded in Barcelona in 1909 and one of the three dominant players in the global blood-plasma industry, alongside CSL and Takeda. It collects human plasma through a large network of donation centers (heavily concentrated in the United States) and fractionates it into therapies, most importantly immunoglobulins (IVIG and subcutaneous Ig) used for immune deficiencies and neurological conditions, plus albumin, alpha-1 antitrypsin, and clotting factors. The business also includes a diagnostics division (blood typing, transfusion screening) and a bio-supplies arm. Revenue comes from selling these plasma-derived medicines to hospitals, specialty pharmacies, and health systems worldwide, with the immunoglobulin franchise the single largest and fastest-growing driver. Grifols trades on the Spanish exchanges under Class A (GRF) and non-voting Class B (GRF.P) shares, and in the US as ADRs under the ticker GRFS. The investment picture is a recovery story layered on a good long-run industry. Plasma is a high-barrier, capital-intensive business with only a handful of scaled competitors and durable demand growth for immunoglobulins. But Grifols entered 2024 heavily indebted after years of debt-funded acquisitions (notably Biotest and Talecris), and in January 2024 short-seller Gotham City Research published a report questioning the company's accounting and its consolidation of related-party entity Scranton, sending the stock down sharply. Since then the company has cut cost-per-liter, grown immunoglobulin volumes, sold its stake in Shanghai RAAS to reduce debt, refinanced looming 2027 maturities, and returned to net-profit growth. A take-private effort by the founding family and Brookfield collapsed in late 2024, and takeover speculation has periodically resurfaced. The result is a stock that is cheaper and more controversial than a plasma leader would normally be, priced for both a genuine operational recovery and unresolved balance-sheet and governance risk.
What's the case for buying GRFS?
1. Immunoglobulin demand and volume growth
The immunoglobulin franchise is Grifols' growth engine, with Ig sales growing roughly 15 percent in Q1 2026 on strong underlying demand for immune-deficiency and neurology indications. New products such as the next-generation IVIG Yimmugo (from the Biotest acquisition) and subcutaneous formats expand the addressable market. Because immunoglobulins are difficult to substitute and demand has grown for years, this franchise gives Grifols a durable, recurring revenue base.
2. Margin recovery from lower cost-per-liter
Much of the story is self-help on the cost side: Grifols has driven down its cost per liter of plasma through more efficient donor centers, automation, and yield improvements, lifting adjusted EBITDA margin back toward the mid-20s percent range. FY2025 adjusted EBITDA rose to roughly EUR 1.8 billion on about 7 percent constant-currency revenue growth. Continued margin expansion, rather than aggressive top-line growth, is management's stated priority.
3. Deleveraging and debt refinancing
The central financial thrust is reducing leverage, which fell from about 4.6x at end-2024 to roughly 4.2x at end-2025 on better EBITDA and cash flow, helped earlier by the sale of the Shanghai RAAS stake to Haier. In April 2026 Grifols refinanced its 2027 maturities with a multi-billion Term Loan B package, pushing out the debt wall and removing a major near-term risk. Every turn of leverage removed shifts more enterprise value toward equity holders.
4. Takeover and strategic optionality
Grifols has repeatedly been the subject of take-private interest, including a Brookfield-and-family effort that collapsed in late 2024 and renewed speculation in 2026. A credible bid could crystallize value, though prior informal approaches were rejected as too low. This optionality cuts both ways: it can support the shares but also injects event-driven volatility unrelated to operations.
What are the risks to GRFS?
Grifols carries a heavy debt load, with leverage still above 4x, so its equity value is sensitive to interest rates, refinancing terms, and any stumble in cash generation. Governance and accounting scrutiny remains a live overhang: the January 2024 Gotham City short report questioned the company's related-party consolidation (Scranton) and internal controls, and while the company rejected the allegations, the episode damaged trust and the discount has not fully closed. The plasma business is capital-intensive and exposed to donor-supply fluctuations, regulatory oversight (FDA and EMA), and pricing pressure as competitors including CSL and Takeda discount immunoglobulins. As a US-listed ADR of a euro-reporting company, GRFS is also exposed to EUR/USD currency swings, and a failed or lowball takeover attempt could weigh on sentiment. The company has prioritized debt reduction over shareholder returns, so there is currently little or no dividend cushion.
How is GRFS valued? (as of July 2026)
Snapshot for GRFS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY 2025): ~EUR 7.5 billion (~$8.2 billion)
- Adjusted EBITDA (FY 2025): ~EUR 1.8 billion (~24% margin)
- Net Profit (FY 2025): ~EUR 402 million (more than doubled YoY)
- Q1 2026 Revenue: ~EUR 1.7 billion (+3.3% cc)
- Net Leverage: ~4.2x (down from ~4.6x in 2024)
- Market Capitalization (approx.): ~$7 billion
- ADR Price (approx.): ~$10 to $12
As of July 2026 Grifols trades at a discount to plasma peers like CSL, reflecting its higher leverage and the residual governance overhang rather than weak operations. On enterprise-value terms the shares look inexpensive against roughly EUR 1.8 billion of adjusted EBITDA, but the large net-debt position means most of that enterprise value still sits with lenders, which is exactly why deleveraging is the key equity lever. Analysts generally rate the ADR in the Hold-to-Moderate-Buy range with price targets clustered around $10 to $12.50.
How do you decide if GRFS is a buy?
Rather than asking whether GRFS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold GRFS indirectly through an index or sector ETF before adding more.
For the full picture, see the GRFS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about GRFS against your real portfolio and see your actual exposure before deciding.
The bottom line on GRFS
The bottom line: Grifols's story right now is Immunoglobulin demand and volume growth, with revenue (fy 2025) at ~EUR 7.5 billion (~$8.2 billion). If you believe that narrative continues, the call is about sizing GRFS sensibly and checking overlap with what you own; if you doubt it (the risk: grifols carries a heavy debt load, with leverage still above 4x, so its equity value is sensitive to interest rates, refinancing terms, and any stumble in cash generation.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around GRFS with Walnut
Use Grifols as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is GRFS a good stock to buy right now?
+
The case for Grifols right now is Immunoglobulin demand and volume growth, with revenue (fy 2025) at ~EUR 7.5 billion (~$8.2 billion). If you believe that thesis holds, GRFS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is grifols carries a heavy debt load, with leverage still above 4x, so its equity value is sensitive to interest rates, refinancing terms, and any stumble in cash generation. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Grifols do?
+
Grifols, S.A.
What are the main risks of GRFS?
+
Grifols carries a heavy debt load, with leverage still above 4x, so its equity value is sensitive to interest rates, refinancing terms, and any stumble in cash generation. Governance and accounting scrutiny remains a live overhang: the January 2024 Gotham City short report questioned the company's related-party consolidation (Scranton) and internal controls, and while the company rejected the allegations, the episode damaged trust and the discount has not fully closed. The plasma business is capital-intensive and exposed to donor-supply fluctuations, regulatory oversight (FDA and EMA), and pricing pressure as competitors including CSL and Takeda discount immunoglobulins. As a US-listed ADR of a euro-reporting company, GRFS is also exposed to EUR/USD currency swings, and a failed or lowball takeover attempt could weigh on sentiment. The company has prioritized debt reduction over shareholder returns, so there is currently little or no dividend cushion.
What does Grifols (GRFS) do?
+
Grifols is a Spanish healthcare company and one of the world's three largest producers of plasma-derived medicines. It collects human plasma at donation centers, mostly in the US, and turns it into therapies such as immunoglobulins, albumin, alpha-1 antitrypsin, and clotting factors, and it also runs a diagnostics business. GRFS is the US-listed ADR of Grifols, S.A.
Is GRFS a good stock to buy right now?
+
That depends on an investor's goals, risk tolerance, and time horizon. GRFS is a recovery-and-deleveraging story on top of an attractive plasma oligopoly, with improving margins and immunoglobulin growth on one side and high debt plus a governance overhang on the other. It is more volatile and controversial than a typical plasma leader, so it fits investors comfortable with turnaround risk. No single answer fits everyone.
Why did Grifols stock crash in 2024?
+
In January 2024 short-seller Gotham City Research published a report questioning Grifols' accounting, its debt calculations, and its consolidation of related-party entity Scranton, sending the shares down sharply. Grifols rejected the allegations, but the report, combined with an already heavy debt load and a collapsed take-private effort later that year, kept a discount on the stock into 2025 and 2026.
Does GRFS pay a dividend?
+
Grifols has prioritized reducing its debt over paying dividends, and it suspended its ordinary dividend during the deleveraging period. As of July 2026 the ADR does not offer a meaningful dividend yield, so investors are relying on operational recovery and balance-sheet improvement rather than income. Any resumption of dividends would depend on leverage falling further and board approval.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell GRFS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.